Pfizer Investigational Site
Gainesville, Florida, 32608, United States
NCT Number: NCT00832052
Evaluate the safety and tolerability of PF-04447943 after administration of multiple doses in healthy elderly participants. Evaluate plasma drug levels and effects on cognition.
Looking for future studies?
Notify MeHealthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
Time frame: For cohorts 1-3, up to 17 days; for cohort 4, up to 24 days.
Time frame: For cohorts 1-3, days 1 and 7; for cohort 4, days 1 and 14
Time frame: 1 hour post dose day 4
Time frame: For cohorts 1-3, days 2, 3, 4, and 7; for cohort 4, days 2, 3, 4, 12, and 13
Time frame: For cohorts 1-3, day 7; for cohort 4, day 14
Time frame: For cohorts 1-3, up to 17 days; for cohort 4, up to 24 days.
Pfizer
Industry
An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 Up To An Exposure Cap In Healthy Elderly Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03929250
Elderly, Healthy
Portland, Oregon, United States
View Trial DetailsNCT01035372
Elderly, Healthy
San Francisco, California, United States
View Trial DetailsNCT03627273
Elderly, Healthy
Brussels, Belgium
View Trial DetailsNCT02968888
Elderly, Healthy
Oslo, Norway
View Trial Details